Results · Apr-Jun 2026
Marksans Pharma Q1 FY27 results
BlockbusterBlockbuster: sales up 20% or more & profit up 30% or more on the same quarter last year, with a wider operating margin.
Sales grew 36% to ₹841 crore from ₹620 crore in Apr-Jun 2025.
Operating profit grew 113% to ₹213 crore, an operating margin of 25.3% (up 9.2 points from a year ago).
Net profit grew 174% to ₹159 crore from ₹58.2 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales −2%, net profit +7%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 840.8 | 620.0 | +36% |
| Operating profit (EBITDA) | 213.0 | 100.1 | +113% |
| Operating margin | 25.3% | 16.1% | +9.2 pts |
| Net profit | 159.4 | 58.2 | +174% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.